Back to Search
Start Over
Consolidation treatment with dexamethasone and alpha-2B recombinant interferon further reduces the M-component level in multiple myeloma patients responding to conventional induction chemotherapy.
- Source :
-
Haematologica [Haematologica] 1990 Nov-Dec; Vol. 75 (6), pp. 576-8. - Publication Year :
- 1990
-
Abstract
- Three patients with symptomatic multiple myeloma who had achieved an objective response after conventional induction chemotherapy were treated with alpha-2b-interferon plus intermittent high-dose dexamethasone as consolidation therapy. This treatment included three mega units of alpha-2b-interferon three times a week, plus 4 days pulsed high-dose dexamethasone every 28 days for 6 months. Toxicity was limited to a mild flu-like syndrome. A further and significant M-component reduction (50%), obtained after conventional chemotherapy, suggests the value of intermittent high-dose dexamethasone plus interferon as consolidation therapy.
- Subjects :
- Combined Modality Therapy
Humans
Interferon alpha-2
Melphalan administration & dosage
Multiple Myeloma blood
Multiple Myeloma drug therapy
Prednisone administration & dosage
Recombinant Proteins
Remission Induction
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Dexamethasone therapeutic use
Immunologic Factors therapeutic use
Interferon-alpha therapeutic use
Multiple Myeloma therapy
Myeloma Proteins analysis
Subjects
Details
- Language :
- English
- ISSN :
- 0390-6078
- Volume :
- 75
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Haematologica
- Publication Type :
- Academic Journal
- Accession number :
- 2098302